Source-grounded facts extracted from TEVA PHARMACEUTICAL INDUSTRIES LTD's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Ratification of appointment of Kesselman & Kesselman (PricewaterhouseCoopers) as independent registered public accounting firm at the 2026-05-28 meeting.
“The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2027 annual meeting of shareholders, as follows: For Against Abstain Broker non-votes 880,542,242 36,085,507 525,382 0”
Shareholder Votes
TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Advisory (non-binding) vote on compensation for named executive officers at the 2026-05-28 meeting.
“The shareholders approved, on a non-binding advisory basis, the compensation for Teva’s named executive officers listed in the proxy statement for the Annual Meeting, as follows: For Against Abstain Broker non-votes 795,976,042 77,082,847 1,170,026 50,661,570”
Shareholder Votes
TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Election of Director to serve until Teva's 2029 annual meeting at the 2026-05-28 meeting.
“The shareholders elected to appoint the following person to the Board, to serve until Teva’s 2029 annual meeting of shareholders, as follows: For Against Abstain Broker non-votes Dr. Sol J. Barer 627,816,662 245,921,571 530,682 50,661,570”
Earnings Releases
TEVA PHARMACEUTICAL INDUSTRIES LTD reported quarter ended March 31, 2026 results: revenue Revenues of $4.0 billion, EPS GAAP diluted EPS of $0.31. Guidance reaffirmed.
“Q1 2026 Highlights: Revenues of $4.0 billion GAAP diluted EPS of $0.31 Non-GAAP diluted EPS of $0.53 Cash flow used in operating activities of $40 million Free cash flow of $188 million”
Material Agreements
TEVA PHARMACEUTICAL INDUSTRIES LTD amended Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement with the Lenders party to its Revolving Facility Agreement and Bank of America, N.A., as administrative agent (effective 2025-12-10).
“On December 10, 2025, Teva Pharmaceutical Industries Limited (the “Company”) obtained the consent of each of the lenders (the “Lenders”) party to its Revolving Facility Agreement (as defined below) to extend the stated maturity date of the commitments and loans thereunder from April 29, 2027 to April 29, 2028, and to amend certain terms of the financial covenants contained in the Revolving Facility Agreement pursuant to the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement (the “Amendment”).”
Debt Financings
TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of $500,000,000 with The Bank of New York Mellon, as trustee at 6.000% maturing December 1, 2032.
“On May 28, 2025, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €1,000,000,000 aggregate principal amount of 4.125% Senior Notes due 2031 (the “ Euro Notes ”); (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ”), a wholly owned subsidiary of the Company, issued $500,000,000 aggregate principal amount of 6.000% Senior Notes due 2032 (the “ 2032 USD Notes ”); and (iii) Teva Pharmaceutical Finance Netherlands IV B.V. (“ Teva Finance IV ” and, together with Teva Finance II and Teva Finance III, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $700,000,0000 aggregate principal amount of 5.750% Senior Notes due 2030 (the “ 2030 USD Notes ” and, together with 2030 USD Notes, the “ USD Notes ” and together with the Euro Notes, the “ Notes ”).”
Debt Financings
TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of €1,000,000,000 with The Bank of New York Mellon, as trustee at 4.125% maturing June 1, 2031.
“On May 28, 2025, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €1,000,000,000 aggregate principal amount of 4.125% Senior Notes due 2031 (the “ Euro Notes ”); (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ”), a wholly owned subsidiary of the Company, issued $500,000,000 aggregate principal amount of 6.000% Senior Notes due 2032 (the “ 2032 USD Notes ”); and (iii) Teva Pharmaceutical Finance Netherlands IV B.V. (“ Teva Finance IV ” and, together with Teva Finance II and Teva Finance III, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $700,000,0000 aggregate principal amount of 5.750% Senior Notes due 2030 (the “ 2030 USD Notes ” and, together with 2030 USD Notes, the “ USD Notes ” and together with the Euro Notes, the “ Notes ”).”
Chen Lichtenstein was elected as member of the Board at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“the Board elected Mr. Chen Lichtenstein to serve as a member of the Board, effective December 1, 2024”
Matthew Shields was appointed as Executive Vice President, Global Operations at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Mr. Matthew Shields has been appointed as Executive Vice President, Global Operations of Teva and a member of Teva Executive Management, effective June 3, 2024.”
Eric Drapé departed as Executive Vice President, Global Operations at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Mr. Eric Drapé, Executive Vice President, Global Operations, will be leaving Teva Pharmaceutical Industries Ltd.”
Earnings Releases
TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended March 31, 2024 results: revenue $3,819 million, EPS GAAP loss per share of $0.12. Guidance reaffirmed.
“TEVA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND REAFFIRMS 2024 FINANCIAL OUTLOOK • Generics business and AUSTEDO ® growth lead Q1 2024 performance. • Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. • Generics business growth across all regions – increased by 9% in local currency terms globally, compared”
“2024 Business Outlook : Revenues of $15.7 - $16.3 billion Non-GAAP operating income of $4.0-$4.5 billion Adjusted EBITDA of $4.5 - $5.0 billion Non-GAAP diluted EPS of $2.20 - $2.50 Free cash flow of $1.7 - $2.0 billion”
Earnings Releases
TEVA PHARMACEUTICAL INDUSTRIES LTD reported the fiscal year ended December 31, 2023 results: revenue $15.8 billion, EPS $(0.50). Guidance initiated.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended September 30, 2023 results: revenue $3.9 billion, EPS GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60. Guidance raised.
“Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO ® , AJOVY ® and global generics business: Growth of AUSTEDO in North America Growth of AJOVY globally Stable and sustainable generics business in the U.S.; continued growth in Europe and International Markets GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60”
Christine Fox was appointed as Executive Vice President, U.S. Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Ms. Christine Fox will be appointed as Executive Vice President, U.S. Commercial.”
Sven Dethlefs departed as Executive Vice President, North America Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Dr. Sven Dethlefs, Executive Vice President, North America Commercial, will be leaving Teva.”
Prof. Varda Shalev was elected as member of the Board at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“On August 1, 2023, at a meeting of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”), the Board elected Prof. Varda Shalev to serve as a member of the Board, effective September 1, 2023, until Teva’s 2024 annual meeting of shareholders.”
Earnings Releases
TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended June 30, 2023 results: revenue $3,878 million, EPS GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56. Guidance reaffirmed.
“structure, while also reorganizing key business units to enhance operational efficiency. Second Quarter 2023 Consolidated Results Revenues in the second quarter of 2023 were $3,878 million, an increase of 2% compared to the second quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from AUSTEDO and Anda in our North”
Shareholder Votes
TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Ratification of appointment of Kesselman & Kesselman (PwC) as independent auditor at the 2023-06-15 meeting.
“The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2024 annual meeting of shareholders, as follows: For Against Abstain Brokers non-vote 712,745,286 35,777,701 1,019,646 0”
Shareholder Votes
TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders rejected Non-binding advisory vote on executive compensation at the 2023-06-15 meeting.
“The shareholders did not approve, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows: For Against Abstain Brokers non-vote 319,197,368 324,474,010 5,417,079 103,855,164”
Shareholder Votes
TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Election of Directors at the 2023-06-15 meeting.
“The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2026 annual meeting of shareholders, as follows: Directors For Against Abstain Brokers non-vote Dr. Sol J. Barer 490,224,315 153,968,878 4,893,082 103,855,164 Janet S. Vergis 498,422,096 145,733,938 4,930,241 103,855,164”
Jean-Michel Halfon resigned as Director at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“On May 8, 2023, Jean-Michel Halfon informed Teva Pharmaceutical Industries Ltd. (“Teva”) that in light of personal reasons, he will resign from Teva’s Board of Directors (“Board”), effective immediately.”
Earnings Releases
TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended March 31, 2023 results: revenue $3,661 million, EPS GAAP loss per share of $0.18; Non-GAAP diluted EPS of $0.40. Guidance reaffirmed.
“where we will make decisive choices and focus our resources to drive growth and innovation." First Quarter 2023 Consolidated Results Revenues in the first quarter of 2023 were $3,661 million, flat compared to the first quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from generic products in our Europe and”
Debt Financings
TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of €800,000,000 aggregate principal amount of 7.375% Sustainability-Linked Senior Notes due 2029; €500,000,000 aggregate pr with The Bank of New York Mellon, as trustee at 7.375% per annum (2029 Euro Notes); 7.875% per annum (2031 Euro Notes and 2029 U maturing September 15, 2029 for the 2029 Euro Notes and 2029 USD Notes; September 15, 2031 for the 2031 USD Notes and 2031 Euro Notes.
“On March 9, 2023, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €800,000,000 aggregate principal amount of 7.375% Sustainability-Linked Senior Notes due 2029 (the “ 2029 Euro Notes ”) and €500,000,000 aggregate principal amount of 7.875% Sustainability-Linked Senior Notes due 2031 (the “ 2031 Euro Notes ” and, together with the 2029 Euro Notes, the “ Euro Notes ”); and (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ” and, together with Teva Finance II, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $600,000,0000 aggregate principal amount of 7.875% Sustainability-Linked Senior Notes due 2029 (the “ 2029 USD Notes ”) and $500,000,000 aggregate principal amount of 8.125% Sustainability-Linked Senior Notes due 2031 (the “ 2031 USD Notes ” and, together with 2029 USD Notes, the “ USD Notes ” and together with the Euro Note”
Material Agreements
TEVA PHARMACEUTICAL INDUSTRIES LTD entered into Senior Indenture dated March 14, 2018 as supplemented by Fourth Supplemental Indenture dated March 9, 2023 with The Bank of New York Mellon valued at €800,000,000 of 7.375% Sustainability-Linked Senior Notes due 2029; €500,000,000 of 7.875% Sustainab (effective 2023-03-09).
“On March 9, 2023, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €800,000,000 aggregate principal amount of 7.375% Sustainability-Linked Senior Notes due 2029 (the “ 2029 Euro Notes ”) and €500,000,000 aggregate principal amount of 7.875% Sustainability-Linked Senior Notes due 2031 (the “ 2031 Euro Notes ” and, together with the 2029 Euro Notes, the “ Euro Notes ”); and (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ” and, together with Teva Finance II, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $600,000,0000 aggregate principal amount of 7.875% Sustainability-Linked Senior Notes due 2029 (the “ 2029 USD Notes ”) and $500,000,000 aggregate principal amount of 8.125% Sustainability-Linked Senior Notes due 2031 (the “ 2031 USD Notes ” and, together with 2029 USD Notes, the “ USD Notes ” and together with the Euro Note”
Earnings Releases
TEVA PHARMACEUTICAL INDUSTRIES LTD updated its the year and the quarter ended December 31, 2022 guidance (initiated).
“On February 8, 2023, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended December 31, 2022.”
Kåre Schultz retired as President and Chief Executive Officer at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“In order to facilitate an orderly transition, Kåre Schultz and the Company’s Board of Directors have mutually agreed that Mr. Schultz will retire from his current positions as President and Chief Executive Officer, and a member of the Board of Directors, effective December 31, 2022.”
Richard Francis was appointed as President and Chief Executive Officer at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“On November 21, 2022, Teva Pharmaceutical Industries Ltd. (the “Company”) announced that its Board of Directors had appointed Richard Francis to become the Company’s President and Chief Executive Officer, effective January 1, 2023.”
Earnings Releases
TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended September 30, 2022 results: revenue $3,595 million, net income GAAP diluted EPS of $0.05, EPS Non-GAAP diluted EPS of $0.59. Guidance reaffirmed.
“(EXHIBIT 99.1) --- EX-99.1 2 a52958636ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Teva Reports Third Quarter 2022 Financial Results Key financial highlights and outlook Revenues of $3.6 billion GAAP diluted EPS of $0.05 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $543 million Free cash flow of $685 million 2022 revenues outlook revised”
Hafrun Fridriksdottir departed as Executive Vice President, Global R&D at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Dr. Hafrun Fridriksdottir, Executive Vice President, Global R&D, will be leaving Teva Pharmaceutical Industries Ltd.”
Amir Weiss was appointed as Senior Vice President and Chief Accounting Officer at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Amir Weiss, currently Vice President of Finance and Corporate Controller, was promoted to Senior Vice President and Chief Accounting Officer, effective November 24, 2021.”
Andrew Weil departed as Chief Accounting Officer at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Andrew Weil, Teva’s Chief Accounting Officer, will step down from his role as Chief Accounting Officer, effective November 24, 2021.”
Dr. Tal Zaks was elected as Member of the Board at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“elected Dr. Tal Zaks to serve as a member of the Board, effective October 1, 2021”
Brendan O’Grady resigned as Executive Vice President – North America Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Brendan O’Grady, Executive Vice President – North America Commercial, has submitted his resignation from Teva, effective August 15, 2021, in order to pursue other career opportunities.”
Abbas Hussain resigned as Director at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“On July 2, 2021, Abbas Hussain informed Teva Pharmaceutical Industries Limited (“Teva”) that, in light of his new role and increased responsibilities as Chief Executive Officer of Vifor Pharma Group, he would resign from Teva’s Board of Directors, effective as of July 6, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.